Great Point Partners LLC
- SEC CIK
- 0001281446
- Latest filing
- Aug 14, 2026
Holdings in Q2 2026
Holdings as of Jun 30, 2026, filed Aug 14, 2026. Long positions only; changes compare share counts with Q1 2026.
- Positions
- 37
- −2 vs. Q1 2026
- Portfolio value
- $424.4M
- +$16.2M (+4.0%) vs. Q1 2026
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| VORVor Biopharma Inc. | COM NEW | 1,700,000 | $31.3M | 7.4% | −50,000−2.9% | Reduced | History |
| ABVXAbivax S.A. | SPONSORED ADS | 204,314 | $27.2M | 6.4% | +204,314 | New | History |
| VERAVera Therapeutics, Inc. | CL A | 600,836 | $25.8M | 6.1% | +401,488+201.4% | Added | History |
| ZURAZura Bio Ltd | CLASS A ORD SHS | 4,215,930 | $24.9M | 5.9% | 00.0% | Unchanged | History |
| ALMSAlumis Inc. | COM | 856,061 | $24.1M | 5.7% | 00.0% | Unchanged | History |
| SLGLSol-Gel Technologies Ltd. | SHS NEW | 274,363 | $20.3M | 4.8% | 00.0% | Unchanged | History |
| DFTXDefinium Therapeutics, Inc. | COM SHS | 425,000 | $20.0M | 4.7% | +425,000 | New | History |
| ANNXAnnexon, Inc. | COM | 3,500,000 | $20.0M | 4.7% | +1,000,000+40.0% | Added | History |
| ORKAOruka Therapeutics, Inc. | COM | 183,330 | $17.4M | 4.1% | 00.0% | Unchanged | History |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 855,813 | $16.7M | 3.9% | +355,813+71.2% | Added | History |
| SGMTSagimet Biosciences Inc. | COM SER A | 2,029,933 | $15.7M | 3.7% | +2,029,933 | New | History |
| CTNMContineum Therapeutics, Inc. | CL A | 921,481 | $15.1M | 3.6% | +121,283+15.2% | Added | History |
| IMMXImmix Biopharma, Inc. | COM | 1,277,642 | $13.2M | 3.1% | +927,642+265.0% | Added | History |
| CLYMClimb Bio, Inc. | COM | 1,000,000 | $13.0M | 3.1% | −334,130−25.0% | Reduced | History |
| AMLXAmylyx Pharmaceuticals, Inc. | COM | 700,000 | $12.6M | 3.0% | −1,050,000−60.0% | Reduced | History |
| NKTRNektar Therapeutics | COM NEW | 175,000 | $12.2M | 2.9% | −141,453−44.7% | Reduced | History |
| NGNENeurogene Inc. | COM | 352,180 | $11.1M | 2.6% | −147,820−29.6% | Reduced | History |
| LBRXLB Pharmaceuticals Inc | COM SHS | 317,221 | $10.3M | 2.4% | +17,221+5.7% | Added | History |
| IRDOpus Genetics, Inc. | COM | 1,970,187 | $8.10M | 1.9% | +1,645,847+507.4% | Added | History |
| EPRXEupraxia Pharmaceuticals Inc. | COM | 1,200,000 | $7.93M | 1.9% | 00.0% | Unchanged | History |
| DRUGBright Minds Biosciences Inc. | COM NEW | 109,603 | $7.69M | 1.8% | −110,397−50.2% | Reduced | History |
| IFRXInflaRx N.V. | COM | 3,046,557 | $6.82M | 1.6% | +3,046,557 | New | History |
| RLMDRelmada Therapeutics, Inc. | COM | 842,106 | $5.83M | 1.4% | 00.0% | Unchanged | History |
| JATTJATT II Acquisition Corp. | ORD SHS | 500,000 | $5.68M | 1.3% | +500,000 | New | History |
| CGEMCullinan Therapeutics, Inc. | COM | 300,000 | $5.46M | 1.3% | 00.0% | Unchanged | History |
| ALTAltimmune, Inc. | COM NEW | 1,741,232 | $5.29M | 1.2% | +1,741,232 | New | History |
| AMANAmanat Acquisition Corp. | CL A ORD | 500,000 | $5.08M | 1.2% | +500,000 | New | History |
| RZLTRezolute, Inc. | COM NEW | 951,809 | $4.95M | 1.2% | 00.0% | Unchanged | History |
| SLNSilence Therapeutics plc | ADS | 450,000 | $4.94M | 1.2% | −570,489−55.9% | Reduced | History |
| PALIPalisade Bio, Inc. | COM | 2,284,819 | $4.78M | 1.1% | −1,120,938−32.9% | Reduced | History |
| EVMNEvommune, Inc. | COM SHS | 325,000 | $4.32M | 1.0% | 00.0% | Unchanged | History |
| SCYXScynexis Inc | COM | 944,292 | $3.84M | 0.9% | 00.0% | UnchangedConverted for a 1-for-8 split | History |
| ELVNEnliven Therapeutics, Inc. | COM | 70,000 | $3.55M | 0.8% | +70,000 | New | History |
| HUMAHumacyte, Inc. | COM | 3,750,000 | $2.93M | 0.7% | 00.0% | Unchanged | History |
| RNTXRein Therapeutics, Inc. | COM NEW | 2,575,000 | $2.68M | 0.6% | +2,575,000 | New | History |
| DBVTDBV Technologies S.A. | SPONSORED ADS | 156,906 | $2.57M | 0.6% | +156,906 | New | History |
| PMNProMIS Neurosciences Inc. | COM SHS | 86,150 | $1.13M | 0.3% | −285,252−76.8% | Reduced | History |
Options (5)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
Sold out since Q1 2026 (12)
Positions held at the end of Q1 2026 that are gone from this filing.
| Security | Class | Shares in Q1 2026 | Value in Q1 2026 | % of portfolio in Q1 2026 | History |
|---|---|---|---|---|---|
| APGEApogee Therapeutics, Inc. | COM | 374,000 | $31.5M | 7.7% | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 675,000 | $13.6M | 3.3% | History |
| IMVTImmunovant, Inc. | COM | 545,625 | $13.6M | 3.3% | History |
| JBIOJade Biosciences, Inc. | COM NEW | 964,462 | $13.6M | 3.3% | History |
| ZBIOZenas BioPharma, Inc. | COM | 524,066 | $10.2M | 2.5% | History |
| CMPXCompass Therapeutics, Inc. | COM | 1,350,000 | $7.14M | 1.7% | History |
| CNTXContext Therapeutics Inc. | COM | 2,238,496 | $5.86M | 1.4% | History |
| UNCYUnicycive Therapeutics, Inc. | COM NEW | 796,558 | $5.24M | 1.3% | History |
| TENXTenax Therapeutics, Inc. | COM NEW | 327,307 | $5.23M | 1.3% | History |
| PHVSPharvaris N.V. | COM | 82,800 | $2.34M | 0.6% | History |
| AVTXAvalo Therapeutics, Inc. | COM NEW | 124,666 | $1.86M | 0.5% | History |
| ALKSAlkermes plc. | SHS | 50,000 | $1.77M | 0.4% | History |